Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WJ05129 in advanced solid tumors
NCT05326035Phase 2Terminated
- Sponsor
- Suzhou Junjing BioSciences
- Start
- Apr 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of WJ05129 in Nonhematologic neoplasms, metastatic solid tumors, sponsored by Suzhou Junjing BioSciences. Started Apr 2022; status: terminated.
02
Drugs
WJ05129
03
Conditions
Nonhematologic neoplasmsmetastatic solid tumors
Beyond the preview
Go deeper on NCT05326035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05326035.